ID: ALA1614664

Max Phase: Preclinical

Molecular Formula: C30H16O9

Molecular Weight: 520.45

Molecule Type: Small molecule

Representations

Synonyms (1): Pseudohypericin
Synonyms from Alternative Forms(1):

Canonical SMILES:  Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(CO)c8c1c2c(c34)c(c65)c78

Standard InChI:  InChI=1S/C30H16O9/c1-7-2-9(32)19-23-15(7)16-8(6-31)3-10(33)20-24(16)28-26-18(12(35)5-14(37)22(26)30(20)39)17-11(34)4-13(36)21(29(19)38)25(17)27(23)28/h2-5,31-37H,6H2,1H3

Standard InChI Key:  YXBUQQDFTYOHQI-UHFFFAOYSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 520.45

Molecular Weight (Monoisotopic): 520.0794

AlogP: 4.26

#Rotatable Bonds: 1

Polar Surface Area: 175.75

Molecular Species: ACID

HBA: 9

HBD: 7

#RO5 Violations: 2

HBA (Lipinski): 9

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 6.04

CX Basic pKa: 3.36

CX LogP: 6.42

CX LogD: 4.40

Aromatic Rings: 8

Heavy Atoms: 39

QED Weighted: 0.12

Np Likeness Score: 0.86

References

1. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]

2. Sorrentino F, Karioti A, Gratteri P, Rigobello MP, Scutari G, Messori L, Bindoli A, Chioccioli M, Gabbiani C, Bergonzi MC, Bilia AR..  (2011)  Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.,  19  (1): [PMID:21106380] [10.1016/j.bmc.2010.10.045]

Source

Source(1):

• Scientific Literature